← Leaderboards
William Flood
Pennsylvania State Univ Hershey Med Ctr
$4,465
Attributed
$4,465
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$4,465 · 3
By mechanism
M01$4,465 · 3
Top collaborators
No co-investigators on record.
Most similar at Pennsylvania State Univ Hershey Med Ctr
Same institution · by research overlap
- Kevin Finnbar Staveleyo'carroll$5,239,458
- Neil D Christensen$4,364,737
- Karam E El-Bayoumy$14,292,983
- Jill P Smith$5,480,175
- Craig M Meyers$12,916,148
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationDrug Screening /EvaluationPaclitaxelColony Stimulating FactorCombination Cancer TherapyCombination ChemotherapyDisease /Therapy DurationDrug Adverse EffectHead /Neck NeoplasmInjuryLong Term SurvivorMetastasisMonoclonal AntibodyNeoplasm /Cancer ChemotherapyNeoplasm /Cancer Classification /StagingNeoplasm /Cancer ImmunotherapyNeoplasm /Cancer Radiation TherapyNeoplastic ProcessNonsmall Cell Lung CancerOral MucosaOral Pharyngeal DisorderBiotechnology
Grant awards (4)
TRIAL PACLITAXEL + CARBOPLATIN W/WO BEVACIZUMAB IN ADV NONSQUAMOUS NSCLC$2,720
M01 · FY2005 · RR
Paclitaxel /Carboplatin/Bevacizumab in Advanced NSCLC$1,163
M01 · FY2004 · RR
Trial of Paclitaxel &Paclitaxel/Cisplatin/radiation H/N$291
M01 · FY2004 · RR
Phase III Trial of GM-CSF in Musocal Injury$291
M01 · FY2004 · RR